Castle Biosciences, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the three Class I director nominees listed below to hold office until the 2029 Annual Meeting of Stockholders: Ellen Goldberg

Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Ellen Goldberg”): 15,455,265 for, 7,118,166 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 6,841,135 for, 2,362,159 withheld, 18,348 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect the three Class I director nominees listed below to hold office until the 2029 Annual Meeting of Stockholders: Miles D. Harrison

Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Miles D. Harrison”): 15,607,369 for, 6,966,062 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 6,843,821 for, 2,362,003 withheld, 15,817 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect the three Class I director nominees listed below to hold office until the 2029 Annual Meeting of Stockholders: Tiffany P. Olson

Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Tiffany P. Olson”): 14,380,655 for, 8,192,776 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 6,573,359 for, 2,497,748 withheld, 150,534 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.

Castle Biosciences, Inc.’s own tally for this item (“3. Approval of the Compensation of the Company's Named Executive Officers”): 21,280,180 for, 1,281,394 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchan…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 71 managers: 9,157,087 for, 78,978 against, 1,239 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 179 managers: 13,563,841 for, 1,164,863 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve our non-employee director compensation policy.

Castle Biosciences, Inc.’s own tally for this item (“4. Approval of the Company's Non-Employee Director Compensation Policy”): 21,394,330 for, 1,130,133 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Company's Non-Employee Director Compensation Policy The Company's stockholders approved the Company's non-employee director compensation policy as described in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 9,162,723 for, 109,387 against.

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

Description as filed by funds: To ratify the selection of KPMG LLP by the Audit Committee of our Board of Directors as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Castle Biosciences, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 24,531,366 for, 445,666 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company's Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December …”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 9,222,564 for, 1 against, 1,239 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.